Clinical Trials on Carcinoma, Diffuse Type

Total 63480 results

Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Gastric Cancer | Diffuse Type Carcinoma

China
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
Stanford University

Withdrawn

School Response to Families Who Have Children With Cancer

Adenocarcinoma | Squamous Cell Carcinoma | Carcinomas

United States
Stanford University

Completed

Symptom Assessment With Patient Surveys

Adenocarcinoma | Squamous Cell Carcinoma | Carcinomas

United States
National Cancer Institute (NCI)

Withdrawn

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Diffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
UNC Lineberger Comprehensive Cancer Center
Cephalon

Completed

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell Lymphoma

United States
University of Western Ontario, Canada

Completed

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Neuroendocrine Carcinoma (Carcinoid)

Canada
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
Centre Hospitalier Universitaire Dijon

Not yet recruiting

Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region (LymphoVi)

Follicular Lymphoma | Diffuse Large Cell Diffuse Lymphoma

France
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Recurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed Adenocarcinoma

United States, Canada
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Carcinomas

France
University of Arizona

Terminated

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

Basal Cell Carcinomas

United States
University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Centre Hospitalier Universitaire de Nice

Completed

In Vivo Damage Induced bu UV in the Epidermis of the Scalp

Squamous Cell Carcinomas

France
Dana-Farber Cancer Institute
Bayer; AbbVie

Active, not recruiting

Copanlisib Plus Venetoclax in R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Radboud University Medical Center

Terminated

Screening for Familial Gastric Cancer in First Degree Relatives (FamGaCan)

Malignant Neoplasm of Stomach | Carcinoma, Diffuse Type | Intestinal Type Adenocarcinoma of Stomach | Relative (Related Person)

Netherlands
Sierra Oncology LLC - a GSK company

Completed

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Lymphoma, Diffuse Large B-Cell

United States, Puerto Rico
Roswell Park Cancer Institute
National Cancer Institute (NCI); Amgen

Active, not recruiting

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma

United States
Medical University of South Carolina
Celgene Corporation

Completed

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Large B-Cell Diffuse Lymphoma

United States
Bispebjerg Hospital

Unknown

Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

Photodynamic Therapy | Basal Cell Carcinomas

Denmark
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (IELSG30)

Large B-cell Diffuse Lymphoma of Testis

Italy, Switzerland
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

United States
National Cancer Institute (NCI)

Completed

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
Spectrum Pharmaceuticals, Inc
Bayer

Terminated

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Lymphoma, Large Cell, Diffuse

Sweden, United States, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Poland, Finland, Canada, France, Germany, Portugal, Thailand, Belgium, Austria, Ireland, Singapore, Switzerland
Case Comprehensive Cancer Center

Active, not recruiting

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Autolus Limited

Completed

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell Lymphoma

United States, United Kingdom
Washington University School of Medicine

Completed

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma

Lymphoma | Diffuse Large Cell

United States
Chonbuk National University Hospital
Consortium for Improving Survival of Lymphoma

Completed

Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma

Large B Cell Diffuse Lymphoma

Korea, Republic of
University of Nebraska
National Cancer Institute (NCI); Genta Incorporated

Terminated

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Fox Chase Cancer Center
Genentech, Inc.

Withdrawn

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Rutgers University

Unknown

An Investigation of Small Intestinal Carcinoid Carcinoma in Families

Carcinoid Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Adult Diffuse Large Cell Lymphoma

Canada
Epizyme, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety of Tazemetostat (TRuST)

Advanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)

United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
David Rizzieri, MD
Novartis Pharmaceuticals

Terminated

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Lymphoma, Large-Cell, Diffuse

United States
Nordic Nanovector

Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell Lymphoma

Spain, United Kingdom, Italy, United States, Germany
Incyte Corporation

Completed

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Lymphoma | Diffuse Large Cell Lymphoma

United States
Eli Lilly and Company

Completed

Chemotherapy for Participants With Lymphoma

Lymphoma, Large Cell, Diffuse

France, Germany, Russian Federation
BeiGene

Recruiting

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Completed

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Pharmacyclics LLC.
Celgene Corporation

Completed

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma Refractory | Diffuse Large B Cell Lymphoma Relapsed

United States
CureTech Ltd

Completed

CT-011 MAb in DLBCL Patients Following ASCT

Primary Mediastinal Large B-Cell Lymphoma | Lymphoma, Large Cell, Diffuse | Lymphoma, Mixed Cell, Diffuse

United States, Israel, India
Herlev Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study (COO-CNS)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
Fudan University

Completed

Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)

Cisplatin | Adenoid Cystic Carcinomas

China
Novartis Pharmaceuticals

Terminated

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Austria, Australia
University Hospital, Bordeaux
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions (MITOSKIN)

Basal Cell Carcinomas | Cutaneous Squamous Cell Carcinoma

France

Clinical Trials on Carcinoma, Diffuse Type

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations